State Street’s Enveric Biosciences ENVB Stock Holding History

State Street’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	-$19K	–	4940
2022 Q2	$19K	Hold	10	–	–	﹤0.01%	4878
2022 Q1	$30K	Hold	10	–	–	﹤0.01%	4860
2021 Q4	$83K	Hold	10	–	–	﹤0.01%	4613
2021 Q3	$184K	Hold	10	–	–	﹤0.01%	4381
2021 Q2	$212K	Buy	+10	New	+$214K	﹤0.01%	4197

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street's ENVB Position: Q3 2022 in Review

State Street sold out of Enveric Biosciences (ENVB) in Q3 2022, closing a stake of 10 shares — an estimated $19K sold.

State Street first reported a position in ENVB in Q2 2021 and held it in 5 quarters. The position peaked at $212K in Q2 2021. 9 funds tracked by Wall St. Rank hold ENVB as of Q3 2022.

State Street reported no remaining Enveric Biosciences position as of Q3 2022 after selling out during the quarter.
State Street sold 10 Enveric Biosciences shares in Q3 2022, an estimated $19K.
State Street first reported a position in Enveric Biosciences in Q2 2021 and held it in 5 quarters.
State Street's Enveric Biosciences position peaked at $212K in Q2 2021.
9 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2022.

Based on State Street's 13F filing for Q3 2022, filed 15 Nov 2022.